Kalvista Pharmaceuticals (NASDAQ:KALV) Shares Gap Down After Earnings Miss

Shares of Kalvista Pharmaceuticals Inc (NASDAQ:KALV) gapped down before the market opened on Monday following a dissappointing earnings announcement. The stock had previously closed at $13.84, but opened at $13.44. Kalvista Pharmaceuticals shares last traded at $13.61, with a volume of 733 shares.

The specialty pharmaceutical company reported ($0.61) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.01). Kalvista Pharmaceuticals had a negative return on equity of 31.21% and a negative net margin of 229.45%.

A number of analysts have recently issued reports on KALV shares. ValuEngine lowered shares of Kalvista Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, September 1st. Zacks Investment Research downgraded shares of Kalvista Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday. HC Wainwright restated a “buy” rating on shares of Kalvista Pharmaceuticals in a research note on Thursday, July 2nd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $25.00 price target on shares of Kalvista Pharmaceuticals in a research note on Wednesday, July 1st. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $22.67.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Citigroup Inc. lifted its stake in Kalvista Pharmaceuticals by 53.6% during the first quarter. Citigroup Inc. now owns 3,887 shares of the specialty pharmaceutical company’s stock worth $30,000 after purchasing an additional 1,357 shares during the last quarter. BNP Paribas Arbitrage SA raised its holdings in shares of Kalvista Pharmaceuticals by 155.6% during the first quarter. BNP Paribas Arbitrage SA now owns 4,604 shares of the specialty pharmaceutical company’s stock worth $35,000 after purchasing an additional 2,803 shares during the period. Invesco Ltd. bought a new position in shares of Kalvista Pharmaceuticals in the 1st quarter worth about $83,000. Quantitative Systematic Strategies LLC acquired a new position in shares of Kalvista Pharmaceuticals in the 2nd quarter valued at about $132,000. Finally, Alliancebernstein L.P. grew its position in shares of Kalvista Pharmaceuticals by 21.8% during the 1st quarter. Alliancebernstein L.P. now owns 12,300 shares of the specialty pharmaceutical company’s stock valued at $94,000 after buying an additional 2,200 shares during the last quarter. Institutional investors and hedge funds own 89.09% of the company’s stock.

The stock’s fifty day simple moving average is $12.42 and its 200-day simple moving average is $11.13. The stock has a market cap of $248.49 million, a P/E ratio of -8.46 and a beta of 2.44.

About Kalvista Pharmaceuticals (NASDAQ:KALV)

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

See Also: What is the Hang Seng index?  

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.